

ASTCT Pharmacy SIG Journal Club Session – May 19, 2021

PRESENTERS & ARTICLES

Jordyn Higgins, PharmD

PGY-2 Oncology Pharmacy Resident

Emory University Hospital Midtown/Winship Cancer Institute

- Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study- Jordyn Higgins, PharmD ([https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736\(20\)31366-0.pdf](https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(20)31366-0.pdf))

Jordanne Adolphsen, PharmD

PGY-2 Oncology Pharmacy Resident

The University of Kansas Health System

jadolphsen@kumc.edu

- Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma (<https://www.nejm.org/doi/full/10.1056/NEJMoa2024850>)

Session Learning Objectives:

Upon completion of the activity, participants should be able to:

1. Discuss recent BMT pharmacy studies and their applications to current practice.
2. Evaluate the safety and efficacy of liso-cel for the treatment of large B-cell lymphomas (LBCL).
3. Assess the efficacy and safety of ide-cel in patients with triple exposed relapsed and refractory myeloma and to evaluate the pharmacokinetics, immunogenicity and potential biomarkers for response and progression.

TARGET AUDIENCE

This activity is intended for pharmacists.

ACCREDITED PROVIDER

This activity is jointly provided by The France Foundation and ASTCT.



CREDIT DESIGNATION

Pharmacists



The France Foundation is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education and will award 1.0 CEU to pharmacists who complete the activity, complete the registration and evaluation forms, and successfully pass a posttest (>75%). There is no fee to participate in this activity. This is a knowledge-based educational activity. Your CE credits will be submitted electronically to the CPE Monitor. CE providers must upload participant information within 60 days from the date the participant completed the activity. **Please submit all evaluations and credit**

requests no later than 30 days after you complete this activity to ensure your credit fulfillment, as CE credit cannot be awarded past 60 days from the activity date.

ACPE No. UAN: 0391-9999-21-160-L01-P.

DISCLOSURE POLICY

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) and the American Society for Transplantation and Cellular Therapy (ASTCT) that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF and ASTCT resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF and ASTCT seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and ASTCT are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

DISCLOSURES

Name of Individual	Individual's Role in Activity	Name of Commercial Entity	Nature of Relationship(s)	Mechanism(s) implemented to resolve conflict of interest
Jordyn Higgins, PharmD	Faculty	NA	NA	NA
Jordanne Adolphsen, PharmD	Faculty	NA	NA	NA
Anthony Proli, PharmD	Content Reviewer	NA	NA	NA
Kelly Hawks, PharmD	Planner	NA	NA	NA
Lauren Curry, PharmD	Planner Session Moderator	NA	NA	NA
Leslie LaMontagne, PharmD	Planner	NA	NA	NA
Mariana Lucena, PharmD	Content Reviewer	NA	NA	NA
Jessica Scott	ASTCT Staff	NA	NA	NA
Heather Tarbox, MPH	TFF Staff	NA	NA	NA
Ted Bruno, MD	TFF Staff, Content Reviewer	NA	NA	NA

DISCLOSURE OF UNLABELED USE

TFF and ASTCT require CE faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and ASTCT do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

DISCLAIMER

TFF and ASTCT present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the

professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and ASTCT assume no liability for the information herein.

CONTACT INFORMATION

If you have questions about this CE activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.